Spots Global Cancer Trial Database for Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Official Title: A Randomized, Double-blind, Placebo-controlled Clinical Study on Prevention and Treatment of CINV Induced by TC Regimen in Gynecological Malignant Tumors
Study ID: NCT06007586
Conditions
Interventions
Study Description
Brief Summary: To determine the best method to prevent CINV caused by TC regimen in patients with gynecological malignant tumor.
Detailed Description: The risk of vomiting caused by high-dose carboplatin is controversial, and there is currently no prevention of TC in patients with gynecological malignant tumors High-level evidence-based medical evidence for programme-induced CINV. Therefore, different guidelines recommend the best antiemetic regimen as well It's different. This study is intended to conduct a prospective, multicenter, randomized, double-blind, placebo-controlled, crossover study The designed Phase III clinical study provides important data and basis for clinical practice and guideline formulation.
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Dengfeng Wang, Chengdu, Sichua, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
